DeepCyte launched DeeTox Atlas, a single-cell metabolomic reference atlas intended to map drug toxicity mechanisms. The company said the foundation dataset combines perturbation studies spanning roughly 100 toxicant compounds and hundreds of thousands of single cells to anchor toxicity-mechanism predictions to established adverse outcome pathways (AOPs). At the same time, EVERSANA expanded an AI-powered commercialization platform with new medical affairs and market research capabilities, adding MLR automation and analytics designed to streamline regulated pharma workflows. Together, the moves reflect faster adoption of AI systems across both discovery-adjacent safety modeling and commercialization operations—areas that often remain bottlenecks for speed-to-decision. EVERSANA’s platform expansion and DeepCyte’s dataset launch both point to an industry push toward scalable, reusable models that reduce the need for compound-by-compound wet lab generation while supporting governance and compliance expectations.